Hepatocellular carcinoma progression in hepatitis B virus-related cirrhosis patients receiving nucleoside (acid) analogs therapy: A retrospective cross-sectional study

Table 2 Univariate logistic regression analysis of hepatitis B-related cirrhosis progressing to hepatocellular carcinoma in patients treated with nucleos(t)ide analogs

Characteristic	No-HCC group (n = 145)	HCC group (n = 121)	Univariate adjusted HR (95%CI)	P value
Age, yr
≥ 60	40 (27.6)	65 (52.9)	2.664 (1.606-4.418)	0.001
< 60	105 (72.4)	56 (46.3)
HBV + alcohol
Yes	31 (21.4)	45 (37.2)	2.384 (1.271-4.473)	0.007
No
Smoking history
Yes	21 (14.5)	51 (42.1)	4.073 (2.281-7.273)	< 0.001
No
Family history of HBV-related HCC
Yes	10 (6.9)	23 (19.0)	3.546 (1.573-7.998)	0.002
No
LAM resistance
Yes	18 (12.4)	27 (22.3)	2.284 (1.214-4.297)	0.011
No
HBV DNA negative
Yes	67 (46.2)	39 (32.2)	0.559 (0.339-0.922)	0.023
No
ALB (g/L)
< 35	67(46.2)	62(51.2)	1.223 (0.754-1.984)	0.414
≥ 35	78 (53.8)	59 (48.8)
ALT (U/L)
50-100	13 (9.0)	15 (12.4)	1.324 (0.612-2.866)	0.476
> 100	10 (7.0)	14 (11.6)	1.138(0.482-2.688)	0.768
AST (U/L)
40-80	32 (22.1)	24 (19.8)	0.919 (−0.713-0.514)	0.783
> 80	16 (10.3)	31 (29.8)	2.899 (0.436-1.767)	0.002
GGT (U/L)
60-120	15 (10.3)	20 (16.5)	1.853 (0.892-3.847)	0.098
> 120	8 (5.1)	28 (23.1)	5.663 (1.075-2.573)	0.001
ALP (U/L)
125-250	36(24.8)	45 (38.8)	1.609 (−0.062-1.028)	0.073
> 250	6 (1.4)	21 (17.4)	4.865 (0.667-2.993)	0.001
FBG (mmol/L)
≥ 6.16	19 (13.1)	37 (30.6)	3.3179 (0.587-1.902)	0.001
< 6.16
Ascites class
Yes	33 (22.8)	43 (35.5)	0.834 (−0.412-0.060)	0.142
No
Child-Pugh class
A	81 (58.6)	55 (37.9)	0.658 (−0.938-0.064)	0.091
B	38 (26.2)	26 (21.5)	0.671 (−0.981-0.112)	0.165
C	26 (17.9)	40 (33.1)	2.260 (0.247-1.427)	0.005

Data are n (%) or mean ± SD as shown. AFP: Alpha-fetoprotein; ALP: Alkaline phosphatase; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; CI: Confidence interval; FBG: Fasting blood glucose; GGT: Glutamyl transpeptidase; HBV: Hepatitis B virus; HCC: Hepatocellular carcinoma; HR: Hazard ratio; LAM: Lamivudine. .